Stemline Therapeutics, Inc.
(NASDAQ : STML)

( )
STML After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
2.59%282.271.4%$834.68m
AMGNAmgen, Inc.
1.08%220.861.3%$513.58m
CELGCelgene Corp.
0.00%110.021.3%$462.62m
GILDGilead Sciences, Inc.
1.98%65.071.0%$394.92m
ILMNIllumina, Inc.
2.53%305.993.5%$310.20m
VRTXVertex Pharmaceuticals, Inc.
2.34%209.801.9%$306.11m
REGNRegeneron Pharmaceuticals, Inc.
1.92%344.872.6%$266.59m
EXASEXACT Sciences Corp.
3.55%82.0524.0%$204.39m
ALXNAlexion Pharmaceuticals, Inc.
2.34%108.372.0%$184.52m
SGENSeattle Genetics, Inc.
1.29%114.756.1%$136.97m
BMRNBioMarin Pharmaceutical, Inc.
-0.71%75.044.3%$119.46m
SRPTSarepta Therapeutics, Inc.
0.05%97.4614.6%$114.07m
AAgilent Technologies, Inc.
1.95%78.261.6%$103.48m
NBIXNeurocrine Biosciences, Inc.
2.89%113.055.0%$89.30m
BGNEBeiGene Ltd.
0.94%198.252.1%$85.33m

Company Profile

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.